# Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 8.2 | 97.1 | (41.8-191.4) |  | Male | 14 | 5.4 | 257.1 | (140.5-431.5) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 1.6 | 313.2 | (100.9-730.9) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.8 | nc | (nc-nc) |
| Female | 35 | 34.0 | 102.9 | (71.7-143.2) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 9.3 | 96.9 | (44.2-183.9) |  |  |  |  |  |  |
| Female | 4 | 7.8 | nc | (nc-nc) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 31 | 28.5 | 108.8 | (73.9-154.4) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 6 | 2.6 | 230.9 | (84.3-502.5) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 8 | 6.2 | 130.1 | (56.0-256.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 8 | 7.7 | 104.2 | (44.9-205.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 14 | 15.3 | 91.6 | (50.0-153.7) |  | Male | 106 | 111.8 | 94.8 | (77.6-114.6) |
| Female | 9 | 15.2 | 59.2 | (27.0-112.4) |  | Female | 95 | 108.0 | 88.0 | (71.2-107.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

214

# Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 20.0 | 85.1 | (49.5-136.3) |  | Male | 23 | 13.0 | 176.9 | (112.1-265.4) |
| Female | 8 | 8.5 | 94.6 | (40.8-186.5) |  | Female | 18 | 11.2 | 160.2 | (94.9-253.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.9 | nc | (nc-nc) |  | Male | 1 | 4.2 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 5 | 3.9 | 128.8 | (41.5-300.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 15 | 11.6 | 129.1 | (72.2-212.9) |
| Female | 98 | 93.6 | 104.7 | (85.0-127.6) |  | Female | 10 | 11.8 | 85.0 | (40.7-156.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 10.2 | 127.3 | (67.7-217.7) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 5 | 5.0 | 100.0 | (32.2-233.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 22.2 | 112.8 | (73.0-166.5) |  |  |  |  |  |  |
| Female | 22 | 24.3 | 90.6 | (56.8-137.2) |  | Female | 6 | 8.1 | 74.4 | (27.2-161.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  | Male | 5 | 7.3 | 68.1 | (22.0-159.0) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 5 | 8.6 | 58.2 | (18.8-135.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 91 | 68.7 | 132.5 | (106.7-162.7) |
| Female | 3 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 11.8 | 76.3 | (34.8-144.8) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 3 | 7.4 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 3.2 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.1 | 86.2 | (34.5-177.7) |  | Male | 11 | 5.2 | 211.8 | (105.6-379.0) |
| Female | 2 | 6.6 | nc | (nc-nc) |  | Female | 23 | 15.7 | 146.1 | (92.6-219.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 7.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.8 | nc | (nc-nc) |  | Female | 25 | 21.7 | 115.3 | (74.6-170.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 36.4 | 74.2 | (48.9-108.0) |  | Male | 283 | 268.7 | 105.3 | (93.4-118.4) |
| Female | 39 | 44.9 | 86.9 | (61.8-118.8) |  | Female | 309 | 312.7 | 98.8 | (88.1-110.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

215

# Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 95 | 96.7 | 98.3 | (79.5-120.2) |  | Male | 72 | 59.7 | 120.7 | (94.4-152.0) |
| Female | 43 | 34.2 | 125.6 | (90.9-169.1) |  | Female | 67 | 46.8 | 143.2 | (110.9-181.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 22 | 17.9 | 122.6 | (76.8-185.6) |  | Male | 31 | 19.4 | 159.8 | (108.6-226.9) |
| Female | 17 | 15.4 | 110.2 | (64.2-176.5) |  | Female | 16 | 15.6 | 102.7 | (58.7-166.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 66 | 53.9 | 122.4 | (94.6-155.7) |
| Female | 434 | 377.4 | 115.0 | (104.4-126.4) |  | Female | 61 | 47.9 | 127.3 | (97.4-163.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 26 | 43.5 | 59.7 | (39.0-87.5) |
| Female | 8 | 12.5 | 64.0 | (27.5-126.0) |  | Female | 32 | 20.3 | 157.9 | (108.0-223.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 88 | 101.9 | 86.4 | (69.3-106.4) |  |  |  |  |  |  |
| Female | 76 | 100.7 | 75.4 | (59.4-94.4) |  | Female | 46 | 32.6 | 141.1 | (103.3-188.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 12 | 24.3 | 49.3 | (25.5-86.2) |  | Male | 34 | 33.9 | 100.2 | (69.4-140.1) |
| Female | 7 | 6.7 | 105.0 | (42.1-216.4) |  | Female | 49 | 35.1 | 139.6 | (103.3-184.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 7 | 6.9 | 101.9 | (40.8-210.0) |  | Male | 326 | 294.3 | 110.8 | (99.1-123.5) |
| Female | 3 | 6.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 51 | 51.6 | 98.9 | (73.6-130.0) |  | Male | 21 | 22.9 | 91.6 | (56.7-140.0) |
| Female | 19 | 30.0 | 63.3 | (38.1-98.9) |  | Female | 14 | 13.7 | 102.1 | (55.8-171.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 14.1 | 71.1 | (34.0-130.7) |  | Male | 12 | 11.6 | 103.2 | (53.3-180.3) |
| Female | 1 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 37 | 38.5 | 96.1 | (67.7-132.5) |  | Male | 34 | 22.6 | 150.4 | (104.1-210.1) |
| Female | 25 | 28.1 | 88.9 | (57.5-131.2) |  | Female | 87 | 69.0 | 126.0 | (100.9-155.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 25 | 32.3 | 77.5 | (50.1-114.4) |  |  |  |  |  |  |
| Female | 9 | 11.2 | 80.0 | (36.5-151.9) |  | Female | 91 | 84.5 | 107.7 | (86.7-132.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 124 | 170.1 | 72.9 | (60.6-86.9) |  | Male | 1166 | 1218.8 | 95.7 | (90.3-101.3) |
| Female | 157 | 177.5 | 88.5 | (75.2-103.4) |  | Female | 1376 | 1274.1 | 108.0 | (102.4-113.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

216

# Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 11.4 | 70.4 | (30.3-138.8) |  | Male | 20 | 8.6 | 233.1 | (142.3-360.0) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 7.6 | 65.8 | (21.2-153.5) |
| Female | 42 | 37.2 | 112.9 | (81.4-152.7) |  | Female | 1 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.3 | 68.2 | (22.0-159.1) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 14.0 | 85.6 | (44.2-149.5) |  |  |  |  |  |  |
| Female | 7 | 7.8 | 90.3 | (36.2-186.0) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 3.5 | 170.5 | (62.3-371.1) |  | Male | 2 | 4.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 40 | 45.7 | 87.4 | (62.5-119.1) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 8.3 | 133.3 | (66.5-238.5) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 8 | 7.2 | 110.5 | (47.6-217.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 5 | 8.6 | 58.2 | (18.7-135.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 21.7 | 83.0 | (49.2-131.2) |  | Male | 154 | 174.6 | 88.2 | (74.8-103.3) |
| Female | 12 | 14.2 | 84.6 | (43.7-147.9) |  | Female | 103 | 113.7 | 90.6 | (74.0-109.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

217

# North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 17.2 | 98.6 | (57.4-157.9) |  | Male | 5 | 10.4 | 47.9 | (15.4-111.7) |
| Female | 11 | 6.1 | 179.7 | (89.6-321.6) |  | Female | 7 | 7.8 | 89.9 | (36.0-185.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 0 | 2.5 | nc | (nc-nc) |  | Female | 1 | 2.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 8 | 9.3 | 85.7 | (36.9-168.9) |
| Female | 52 | 63.1 | 82.5 | (61.6-108.1) |  | Female | 7 | 8.3 | 84.6 | (33.9-174.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 7.2 | 124.6 | (56.8-236.5) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 17.6 | 147.8 | (96.5-216.6) |  |  |  |  |  |  |
| Female | 16 | 17.5 | 91.5 | (52.3-148.6) |  | Female | 5 | 5.5 | 91.2 | (29.4-212.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 4.2 | 192.8 | (83.0-379.9) |  | Male | 0 | 5.9 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 10 | 6.3 | 159.8 | (76.5-293.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 43 | 47.7 | 90.2 | (65.2-121.4) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 8.7 | 149.9 | (79.7-256.3) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 2 | 5.1 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 4 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.7 | 74.7 | (24.1-174.3) |  | Male | 5 | 3.8 | 131.6 | (42.4-307.2) |
| Female | 3 | 4.8 | nc | (nc-nc) |  | Female | 7 | 10.8 | 64.6 | (25.9-133.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 5.4 | 166.9 | (76.2-316.8) |  |  |  |  |  |  |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 12 | 14.0 | 85.9 | (44.3-150.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 30.2 | 89.4 | (58.9-130.0) |  | Male | 206 | 208.5 | 98.8 | (85.7-113.2) |
| Female | 46 | 31.8 | 144.6 | (105.9-192.9) |  | Female | 209 | 217.0 | 96.3 | (83.7-110.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

218

# North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 42 | 29.3 | 143.5 | (103.4-194.0) |  | Male | 15 | 19.0 | 79.0 | (44.2-130.3) |
| Female | 9 | 11.5 | 78.3 | (35.7-148.7) |  | Female | 16 | 15.6 | 102.7 | (58.7-166.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.9 | 101.2 | (37.0-220.3) |  | Male | 6 | 6.0 | 99.5 | (36.3-216.6) |
| Female | 6 | 5.0 | 119.9 | (43.8-261.0) |  | Female | 6 | 5.2 | 115.4 | (42.1-251.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 19 | 17.1 | 111.0 | (66.8-173.4) |
| Female | 115 | 126.4 | 91.0 | (75.1-109.2) |  | Female | 15 | 15.9 | 94.1 | (52.7-155.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 14.4 | 62.4 | (28.5-118.5) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 3 | 6.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 32.6 | 85.8 | (57.0-124.1) |  |  |  |  |  |  |
| Female | 43 | 34.3 | 125.3 | (90.7-168.8) |  | Female | 8 | 10.8 | 74.0 | (31.8-145.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 7.6 | 79.2 | (28.9-172.4) |  | Male | 10 | 10.5 | 94.9 | (45.4-174.6) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 9 | 11.8 | 76.2 | (34.8-144.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 93 | 91.4 | 101.7 | (82.1-124.6) |
| Female | 4 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 16.7 | 89.8 | (50.2-148.1) |  | Male | 7 | 7.1 | 98.1 | (39.3-202.1) |
| Female | 5 | 10.0 | 50.0 | (16.1-116.8) |  | Female | 7 | 4.7 | 150.1 | (60.1-309.3) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 4.4 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 12.2 | 98.0 | (50.6-171.2) |  | Male | 13 | 7.8 | 165.8 | (88.2-283.6) |
| Female | 11 | 9.3 | 117.9 | (58.8-211.0) |  | Female | 21 | 23.0 | 91.3 | (56.5-139.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 10.5 | 57.3 | (20.9-124.8) |  |  |  |  |  |  |
| Female | 5 | 3.7 | 135.2 | (43.6-315.5) |  | Female | 22 | 27.5 | 80.1 | (50.2-121.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 51.2 | 72.2 | (50.8-99.5) |  | Male | 372 | 382.9 | 97.2 | (87.5-107.6) |
| Female | 47 | 59.1 | 79.5 | (58.4-105.8) |  | Female | 388 | 425.4 | 91.2 | (82.4-100.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

219

# North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 22.5 | 93.5 | (57.8-142.9) |  | Male | 14 | 16.0 | 87.4 | (47.7-146.6) |
| Female | 7 | 8.5 | 82.1 | (32.9-169.3) |  | Female | 22 | 13.4 | 164.1 | (102.8-248.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.4 | 92.1 | (29.7-214.9) |  | Male | 6 | 5.0 | 119.1 | (43.5-259.2) |
| Female | 7 | 4.4 | 158.9 | (63.7-327.5) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 17 | 14.4 | 117.6 | (68.5-188.4) |
| Female | 107 | 108.0 | 99.1 | (81.2-119.7) |  | Female | 14 | 12.7 | 110.2 | (60.2-184.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 13.0 | 84.5 | (42.1-151.3) |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 6 | 5.5 | 109.6 | (40.0-238.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 34 | 26.9 | 126.3 | (87.5-176.5) |  |  |  |  |  |  |
| Female | 23 | 26.5 | 86.9 | (55.1-130.4) |  | Female | 4 | 9.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.4 | 125.0 | (53.8-246.3) |  | Male | 10 | 8.6 | 116.1 | (55.6-213.5) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 9 | 8.8 | 102.7 | (46.9-195.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 84 | 81.8 | 102.7 | (81.9-127.2) |
| Female | 1 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 14.9 | 100.3 | (56.1-165.5) |  | Male | 3 | 5.8 | nc | (nc-nc) |
| Female | 10 | 8.2 | 121.6 | (58.2-223.6) |  | Female | 4 | 3.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 3.8 | 157.4 | (57.5-342.5) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 10.2 | 58.6 | (21.4-127.6) |  | Male | 7 | 7.5 | 93.3 | (37.4-192.2) |
| Female | 6 | 7.6 | 79.0 | (28.9-172.0) |  | Female | 22 | 22.1 | 99.5 | (62.3-150.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 8 | 9.2 | 87.1 | (37.5-171.7) |  |  |  |  |  |  |
| Female | 1 | 2.9 | nc | (nc-nc) |  | Female | 19 | 23.5 | 80.7 | (48.6-126.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 40 | 41.6 | 96.3 | (68.8-131.1) |  | Male | 333 | 325.4 | 102.3 | (91.6-113.9) |
| Female | 41 | 45.0 | 91.2 | (65.4-123.7) |  | Female | 337 | 349.5 | 96.4 | (86.4-107.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

220

# North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 13 | 19.5 | 66.7 | (35.5-114.0) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 5.1 | 136.4 | (54.6-281.0) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 18 | 15.1 | 119.1 | (70.6-188.3) |
| Female | 2 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 8 | 4.2 | 190.0 | (81.8-374.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 8.6 | 105.0 | (47.9-199.4) |  | Male | 68 | 62.5 | 108.7 | (84.4-137.8) |
| Female | 7 | 9.1 | 77.3 | (31.0-159.3) |  | Female | 63 | 65.0 | 96.9 | (74.4-123.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

221

# North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 14.2 | 91.3 | (48.6-156.1) |  | Male | 15 | 9.9 | 152.2 | (85.1-251.1) |
| Female | 9 | 5.4 | 166.0 | (75.7-315.1) |  | Female | 12 | 8.3 | 145.4 | (75.0-254.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 0 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 9 | 8.8 | 101.8 | (46.5-193.3) |
| Female | 83 | 69.2 | 119.9 | (95.5-148.6) |  | Female | 5 | 8.0 | 62.5 | (20.1-145.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.0 | 62.7 | (20.2-146.3) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 1 | 3.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 16.6 | 102.4 | (59.6-164.0) |  |  |  |  |  |  |
| Female | 13 | 16.5 | 78.9 | (42.0-135.0) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 4.1 | 172.8 | (69.2-356.1) |  | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 6 | 5.5 | 108.7 | (39.7-236.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 51 | 51.9 | 98.2 | (73.1-129.1) |
| Female | 2 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 9.2 | 108.9 | (52.2-200.4) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 2 | 5.3 | nc | (nc-nc) |  | Female | 0 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.1 | 146.6 | (66.9-278.2) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 7 | 4.5 | 155.9 | (62.4-321.1) |  | Female | 17 | 13.1 | 130.0 | (75.7-208.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.7 | 87.5 | (28.2-204.3) |  |  |  |  |  |  |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 17 | 15.3 | 111.0 | (64.6-177.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 26.4 | 71.9 | (43.3-112.3) |  | Male | 201 | 202.4 | 99.3 | (86.1-114.1) |
| Female | 25 | 29.8 | 83.8 | (54.2-123.7) |  | Female | 221 | 221.1 | 100.0 | (87.2-114.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

222

# Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 31 | 29.0 | 106.9 | (72.6-151.7) |  | Male | 12 | 18.5 | 64.9 | (33.5-113.3) |
| Female | 11 | 11.2 | 98.5 | (49.1-176.3) |  | Female | 10 | 15.9 | 62.7 | (30.0-115.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.6 | 126.0 | (50.5-259.7) |  | Male | 1 | 6.0 | nc | (nc-nc) |
| Female | 5 | 5.2 | 97.0 | (31.3-226.5) |  | Female | 10 | 5.1 | 194.6 | (93.1-357.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 16 | 16.7 | 96.0 | (54.8-155.9) |
| Female | 166 | 124.5 | 133.3 | (113.8-155.2) |  | Female | 13 | 15.9 | 81.9 | (43.6-140.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 13 | 13.8 | 94.1 | (50.1-161.0) |
| Female | 3 | 4.2 | nc | (nc-nc) |  | Female | 6 | 6.8 | 88.8 | (32.4-193.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 30 | 31.2 | 96.2 | (64.9-137.4) |  |  |  |  |  |  |
| Female | 33 | 32.7 | 101.0 | (69.5-141.8) |  | Female | 15 | 11.0 | 136.6 | (76.4-225.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.6 | 92.1 | (36.9-189.7) |  | Male | 8 | 10.3 | 77.4 | (33.3-152.5) |
| Female | 4 | 2.2 | nc | (nc-nc) |  | Female | 14 | 11.4 | 122.8 | (67.1-206.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 62 | 93.6 | 66.2 | (50.8-84.9) |
| Female | 2 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 16.3 | 49.0 | (21.1-96.6) |  | Male | 6 | 7.0 | 85.8 | (31.3-186.8) |
| Female | 7 | 9.9 | 70.8 | (28.4-145.9) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  | Male | 6 | 4.1 | 147.4 | (53.8-320.9) |
| Female | 3 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 11.6 | 94.6 | (47.1-169.2) |  | Male | 4 | 7.4 | nc | (nc-nc) |
| Female | 7 | 9.2 | 75.9 | (30.4-156.4) |  | Female | 9 | 24.1 | 37.3 | (17.0-70.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 10.1 | 49.7 | (16.0-116.0) |  |  |  |  |  |  |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 36 | 28.7 | 125.6 | (87.9-173.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 39 | 51.7 | 75.4 | (53.6-103.1) |  | Male | 294 | 378.0 | 77.8 | (69.1-87.2) |
| Female | 46 | 58.3 | 79.0 | (57.8-105.3) |  | Female | 440 | 422.2 | 104.2 | (94.7-114.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

223

# Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 16.0 | 131.5 | (81.4-201.0) |  | Male | 9 | 10.3 | 87.4 | (39.9-166.0) |
| Female | 8 | 5.5 | 146.1 | (62.9-288.0) |  | Female | 6 | 7.7 | 78.0 | (28.5-169.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.1 | nc | (nc-nc) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 5 | 2.5 | 199.0 | (64.1-464.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 9 | 9.3 | 97.0 | (44.2-184.1) |
| Female | 80 | 62.4 | 128.1 | (101.6-159.5) |  | Female | 6 | 7.8 | 77.2 | (28.2-168.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.8 | 63.9 | (20.6-149.1) |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 17.9 | 56.0 | (26.8-103.0) |  |  |  |  |  |  |
| Female | 15 | 16.6 | 90.6 | (50.7-149.4) |  | Female | 2 | 5.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 4.1 | 219.1 | (100.0-415.9) |  | Male | 6 | 5.8 | 103.9 | (37.9-226.2) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 6 | 5.6 | 107.5 | (39.2-233.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 48 | 49.7 | 96.5 | (71.2-128.0) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 9.0 | 77.6 | (31.1-159.8) |  | Male | 1 | 3.9 | nc | (nc-nc) |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.5 | 138.5 | (63.2-262.8) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 5 | 4.5 | 109.9 | (35.4-256.6) |  | Female | 9 | 11.5 | 78.5 | (35.8-148.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 15 | 13.7 | 109.1 | (61.0-180.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 28.1 | 46.3 | (24.6-79.1) |  | Male | 179 | 207.7 | 86.2 | (74.0-99.8) |
| Female | 24 | 28.5 | 84.1 | (53.9-125.2) |  | Female | 206 | 208.0 | 99.0 | (86.0-113.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

224

# Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 15.6 | 108.7 | (63.3-174.0) |  | Male | 11 | 10.3 | 107.0 | (53.4-191.5) |
| Female | 6 | 5.6 | 106.4 | (38.9-231.7) |  | Female | 10 | 8.2 | 121.6 | (58.2-223.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.2 | nc | (nc-nc) |  | Male | 10 | 3.3 | 301.4 | (144.3-554.3) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 6 | 9.2 | 65.1 | (23.8-141.7) |
| Female | 53 | 65.3 | 81.2 | (60.8-106.2) |  | Female | 9 | 8.1 | 111.1 | (50.7-210.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.8 | 128.6 | (61.6-236.5) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 17.4 | 57.4 | (27.5-105.6) |  |  |  |  |  |  |
| Female | 24 | 16.9 | 141.9 | (90.9-211.1) |  | Female | 5 | 5.6 | 89.4 | (28.8-208.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 4.1 | nc | (nc-nc) |  | Male | 5 | 5.7 | 87.9 | (28.3-205.1) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.8 | 121.3 | (48.6-249.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 54 | 50.1 | 107.8 | (80.9-140.6) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 9.1 | 154.2 | (84.2-258.7) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 4 | 5.1 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 6.5 | nc | (nc-nc) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 4 | 4.9 | nc | (nc-nc) |  | Female | 11 | 12.8 | 85.7 | (42.7-153.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 21 | 14.4 | 146.0 | (90.3-223.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 28 | 28.2 | 99.4 | (66.0-143.7) |  | Male | 197 | 207.3 | 95.1 | (82.2-109.3) |
| Female | 25 | 29.3 | 85.4 | (55.2-126.1) |  | Female | 213 | 217.8 | 97.8 | (85.1-111.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

225

# Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 11 | 13.9 | 79.4 | (39.6-142.0) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 4.1 | 121.7 | (39.2-283.9) |  |  |  |  |  |  |
| Female | 2 | 3.3 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 13.1 | 53.3 | (21.3-109.8) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 2.2 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 5 | 3.2 | 156.2 | (50.3-364.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 6.6 | nc | (nc-nc) |  | Male | 35 | 50.0 | 70.0 | (48.7-97.3) |
| Female | 5 | 6.2 | 81.0 | (26.1-189.1) |  | Female | 39 | 45.0 | 86.6 | (61.6-118.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

226

# Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 17.5 | 74.3 | (39.5-127.0) |  | Male | 14 | 11.8 | 119.0 | (65.0-199.7) |
| Female | 7 | 6.2 | 113.7 | (45.6-234.3) |  | Female | 11 | 9.3 | 117.8 | (58.7-210.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.8 | 132.8 | (42.8-310.0) |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 7 | 10.6 | 66.0 | (26.5-136.0) |
| Female | 75 | 75.2 | 99.8 | (78.5-125.1) |  | Female | 10 | 9.0 | 110.5 | (52.9-203.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 9.4 | 85.3 | (36.7-168.2) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 20.0 | 129.7 | (84.7-190.0) |  |  |  |  |  |  |
| Female | 20 | 19.0 | 105.2 | (64.3-162.5) |  | Female | 7 | 6.5 | 108.0 | (43.3-222.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.8 | 125.2 | (45.7-272.6) |  | Male | 9 | 6.5 | 139.4 | (63.6-264.7) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 11 | 6.4 | 172.9 | (86.2-309.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 51 | 59.9 | 85.1 | (63.4-111.9) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 10.7 | 130.5 | (71.3-218.9) |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 8 | 5.8 | 138.9 | (59.8-273.6) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 8 | 7.5 | 106.7 | (45.9-210.2) |  | Male | 8 | 5.1 | 155.8 | (67.1-307.0) |
| Female | 8 | 5.3 | 151.9 | (65.4-299.4) |  | Female | 15 | 14.8 | 101.6 | (56.8-167.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 6.7 | 104.3 | (41.8-214.9) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 22 | 16.8 | 131.1 | (82.1-198.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 31.6 | 85.3 | (56.2-124.2) |  | Male | 237 | 240.8 | 98.4 | (86.3-111.8) |
| Female | 26 | 32.3 | 80.6 | (52.6-118.1) |  | Female | 256 | 246.3 | 103.9 | (91.6-117.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

227

# Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 12.5 | 96.1 | (49.6-167.9) |  | Male | 8 | 7.8 | 102.5 | (44.2-202.1) |
| Female | 4 | 4.6 | nc | (nc-nc) |  | Female | 13 | 6.0 | 218.2 | (116.1-373.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 2.4 | 254.4 | (92.9-553.7) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 5 | 2.1 | 239.2 | (77.1-558.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 7 | 7.0 | 99.7 | (39.9-205.4) |
| Female | 48 | 50.1 | 95.8 | (70.7-127.1) |  | Female | 11 | 6.4 | 173.1 | (86.3-309.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.9 | 85.2 | (27.5-198.9) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 5 | 2.7 | 187.6 | (60.4-437.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 13.5 | 73.8 | (35.3-135.7) |  |  |  |  |  |  |
| Female | 8 | 13.5 | 59.1 | (25.4-116.4) |  | Female | 6 | 4.3 | 139.9 | (51.1-304.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  | Male | 4 | 4.4 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 39 | 38.3 | 101.8 | (72.4-139.2) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.8 | 88.0 | (32.1-191.6) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 4 | 8.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 4.3 | 163.0 | (65.3-335.9) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 16 | 11.1 | 144.5 | (82.6-234.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 21.9 | 59.4 | (31.6-101.5) |  | Male | 147 | 159.0 | 92.5 | (78.1-108.7) |
| Female | 13 | 24.2 | 53.8 | (28.6-92.0) |  | Female | 161 | 168.0 | 95.8 | (81.6-111.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

228

# Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 32.1 | 49.9 | (28.5-81.0) |  | Male | 34 | 20.0 | 169.7 | (117.5-237.1) |
| Female | 10 | 12.7 | 78.8 | (37.7-144.9) |  | Female | 25 | 16.5 | 151.5 | (98.0-223.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 6.0 | 166.1 | (79.5-305.5) |  | Male | 7 | 6.4 | 109.0 | (43.7-224.6) |
| Female | 6 | 5.3 | 114.3 | (41.7-248.7) |  | Female | 7 | 5.7 | 123.4 | (49.4-254.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 18 | 17.9 | 100.7 | (59.7-159.2) |
| Female | 137 | 131.0 | 104.6 | (87.8-123.6) |  | Female | 20 | 17.3 | 115.5 | (70.5-178.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 17 | 14.2 | 120.0 | (69.9-192.2) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 6 | 7.1 | 84.1 | (30.7-183.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 52 | 33.9 | 153.4 | (114.6-201.2) |  |  |  |  |  |  |
| Female | 56 | 37.2 | 150.7 | (113.8-195.7) |  | Female | 12 | 11.4 | 105.3 | (54.3-183.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 7.9 | 126.6 | (60.6-232.8) |  | Male | 17 | 11.1 | 153.2 | (89.2-245.3) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 19 | 12.9 | 146.8 | (88.3-229.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 79 | 90.5 | 87.3 | (69.1-108.8) |
| Female | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 16.9 | 82.9 | (45.3-139.1) |  | Male | 10 | 7.6 | 131.2 | (62.8-241.4) |
| Female | 16 | 10.6 | 150.9 | (86.2-245.1) |  | Female | 5 | 5.1 | 98.8 | (31.8-230.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.6 | 153.7 | (61.6-316.7) |  | Male | 7 | 4.4 | 158.0 | (63.3-325.5) |
| Female | 3 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 12.9 | 85.5 | (42.6-153.0) |  | Male | 13 | 7.8 | 167.6 | (89.1-286.6) |
| Female | 12 | 10.1 | 118.7 | (61.3-207.3) |  | Female | 27 | 23.4 | 115.5 | (76.1-168.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 13 | 10.5 | 124.2 | (66.1-212.4) |  |  |  |  |  |  |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 30 | 28.4 | 105.6 | (71.2-150.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 58 | 56.1 | 103.4 | (78.5-133.7) |  | Male | 449 | 397.7 | 112.9 | (102.7-123.9) |
| Female | 87 | 65.3 | 133.3 | (106.8-164.4) |  | Female | 522 | 452.3 | 115.4 | (105.7-125.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

229

# Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 7.6 | 118.2 | (53.9-224.4) |  | Male | 8 | 4.5 | 176.6 | (76.0-348.0) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 4 | 4.0 | nc | (nc-nc) |
| Female | 24 | 24.0 | 100.1 | (64.1-148.9) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 4 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 7.5 | 120.0 | (54.8-227.8) |  |  |  |  |  |  |
| Female | 4 | 6.8 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 5 | 2.6 | 189.0 | (60.9-441.0) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 16 | 21.1 | 75.7 | (43.2-122.9) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.7 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 4 | 3.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 7 | 5.5 | 128.0 | (51.3-263.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 13.8 | 80.0 | (39.9-143.1) |  | Male | 84 | 90.7 | 92.6 | (73.9-114.6) |
| Female | 15 | 12.5 | 119.9 | (67.1-197.8) |  | Female | 81 | 83.2 | 97.3 | (77.3-121.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

230

# Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 7 | 7.5 | 93.8 | (37.6-193.2) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 8 | 7.4 | 107.5 | (46.3-211.9) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 3.9 | nc | (nc-nc) |  | Male | 23 | 29.1 | 78.9 | (50.0-118.5) |
| Female | 1 | 3.0 | nc | (nc-nc) |  | Female | 22 | 23.4 | 94.0 | (58.9-142.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

231

# Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 9.4 | 85.4 | (36.8-168.2) |  | Male | 1 | 6.0 | nc | (nc-nc) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 2 | 4.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 4 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 5.4 | 111.2 | (40.6-242.1) |
| Female | 33 | 35.2 | 93.7 | (64.5-131.6) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.5 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 10.0 | 49.8 | (16.1-116.3) |  |  |  |  |  |  |
| Female | 6 | 8.7 | 69.1 | (25.2-150.4) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 28 | 30.6 | 91.5 | (60.8-132.2) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 5.3 | 131.9 | (52.8-271.8) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 5 | 6.2 | 80.7 | (26.0-188.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 12 | 8.1 | 147.7 | (76.2-258.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 20 | 17.2 | 116.4 | (71.1-179.7) |  | Male | 111 | 123.1 | 90.2 | (74.2-108.6) |
| Female | 19 | 16.3 | 116.7 | (70.3-182.3) |  | Female | 118 | 115.3 | 102.3 | (84.7-122.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

232

# Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 15.4 | 84.2 | (44.8-144.1) |  | Male | 21 | 8.4 | 249.4 | (154.3-381.3) |
| Female | 5 | 5.1 | 98.9 | (31.9-230.7) |  | Female | 12 | 5.3 | 224.3 | (115.8-391.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 13 | 7.5 | 172.8 | (91.9-295.5) |
| Female | 61 | 46.2 | 132.1 | (101.0-169.7) |  | Female | 6 | 6.4 | 93.4 | (34.1-203.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 14.2 | 98.8 | (54.0-165.7) |  |  |  |  |  |  |
| Female | 13 | 13.4 | 97.0 | (51.6-165.8) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 5 | 5.1 | 98.3 | (31.7-229.3) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 8 | 5.1 | 157.7 | (67.9-310.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 32 | 43.8 | 73.1 | (50.0-103.2) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 6.9 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 2 | 3.9 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 5.2 | 190.6 | (91.2-350.5) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 8 | 10.9 | 73.6 | (31.7-145.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 27.6 | 29.0 | (12.5-57.2) |  | Male | 153 | 176.3 | 86.8 | (73.6-101.7) |
| Female | 18 | 26.7 | 67.3 | (39.9-106.4) |  | Female | 175 | 163.2 | 107.2 | (91.9-124.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

233

# Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 14 | 7.6 | 185.0 | (101.1-310.4) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 8.5 | 82.7 | (33.1-170.3) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 4.9 | 141.4 | (56.7-291.4) |  | Male | 24 | 33.8 | 71.1 | (45.5-105.8) |
| Female | 6 | 3.8 | 156.5 | (57.2-340.7) |  | Female | 32 | 25.1 | 127.7 | (87.3-180.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

234

# Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 10.9 | 137.6 | (77.0-227.0) |  | Male | 12 | 7.9 | 151.2 | (78.0-264.1) |
| Female | 6 | 4.9 | 123.1 | (44.9-267.9) |  | Female | 12 | 7.2 | 167.4 | (86.4-292.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 6 | 2.5 | 241.0 | (88.0-524.7) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 11 | 7.1 | 155.0 | (77.3-277.4) |
| Female | 58 | 58.3 | 99.6 | (75.6-128.7) |  | Female | 11 | 7.1 | 155.2 | (77.4-277.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 6.5 | 122.5 | (52.8-241.4) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 13.3 | 82.8 | (41.3-148.2) |  |  |  |  |  |  |
| Female | 15 | 14.5 | 103.2 | (57.7-170.2) |  | Female | 8 | 5.0 | 160.7 | (69.2-316.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 6 | 4.9 | 123.1 | (44.9-267.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 40 | 41.2 | 97.1 | (69.3-132.2) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.5 | 79.6 | (29.1-173.2) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 6 | 4.6 | 131.8 | (48.1-286.9) |  | Female | 3 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 5.0 | 198.4 | (95.0-364.9) |  | Male | 7 | 3.8 | 185.5 | (74.3-382.2) |
| Female | 7 | 4.1 | 172.7 | (69.2-355.9) |  | Female | 15 | 11.1 | 135.2 | (75.6-223.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 4.6 | 197.3 | (90.0-374.5) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 20 | 13.1 | 152.6 | (93.2-235.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 41 | 20.5 | 200.2 | (143.6-271.5) |  | Male | 202 | 161.3 | 125.2 | (108.5-143.7) |
| Female | 26 | 26.1 | 99.5 | (65.0-145.8) |  | Female | 223 | 191.3 | 116.6 | (101.8-132.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

235

# Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 11.1 | 179.7 | (109.7-277.5) |  | Male | 13 | 7.8 | 165.6 | (88.1-283.3) |
| Female | 8 | 4.9 | 163.7 | (70.5-322.5) |  | Female | 7 | 6.7 | 104.6 | (41.9-215.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 2.5 | 279.4 | (111.9-575.8) |  | Male | 1 | 2.5 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.9 | nc | (nc-nc) |
| Female | 61 | 54.1 | 112.7 | (86.2-144.8) |  | Female | 8 | 6.8 | 117.6 | (50.6-231.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.3 | 94.8 | (34.6-206.3) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 13.1 | 99.5 | (52.9-170.1) |  |  |  |  |  |  |
| Female | 13 | 14.2 | 91.6 | (48.7-156.7) |  | Female | 8 | 4.7 | 171.0 | (73.6-337.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 6 | 5.0 | 119.2 | (43.5-259.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 35 | 39.8 | 88.0 | (61.3-122.4) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 7.2 | 209.5 | (117.2-345.6) |  | Male | 5 | 2.9 | 174.8 | (56.3-407.8) |
| Female | 5 | 4.3 | 116.9 | (37.7-272.9) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 1.9 | 261.7 | (84.3-610.7) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 4.8 | 124.5 | (45.5-271.0) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 5 | 3.9 | 127.1 | (41.0-296.6) |  | Female | 8 | 9.8 | 81.3 | (35.0-160.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 13 | 12.2 | 106.2 | (56.5-181.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 31 | 20.9 | 148.2 | (100.7-210.4) |  | Male | 184 | 158.6 | 116.0 | (99.9-134.0) |
| Female | 15 | 25.5 | 58.8 | (32.9-96.9) |  | Female | 182 | 182.0 | 100.0 | (86.0-115.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

236

# Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.1 | 97.7 | (31.5-227.9) |  | Male | 7 | 3.3 | 211.8 | (84.8-436.3) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 19 | 20.2 | 94.0 | (56.6-146.8) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 5.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 6 | 5.1 | 118.0 | (43.1-256.8) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.4 | nc | (nc-nc) |  | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 22 | 17.6 | 124.8 | (78.2-189.0) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 1 | 3.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 5 | 4.8 | 105.2 | (33.9-245.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 9.4 | 52.9 | (17.1-123.6) |  | Male | 74 | 68.9 | 107.3 | (84.3-134.7) |
| Female | 5 | 9.4 | 52.9 | (17.1-123.5) |  | Female | 56 | 67.2 | 83.3 | (62.9-108.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

237

# Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 95 | 74.7 | 127.2 | (102.9-155.5) |  | Male | 40 | 43.8 | 91.2 | (65.2-124.3) |
| Female | 39 | 27.7 | 140.7 | (100.0-192.3) |  | Female | 37 | 33.5 | 110.5 | (77.8-152.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 12.2 | 65.6 | (28.2-129.2) |  | Male | 18 | 14.3 | 125.5 | (74.3-198.3) |
| Female | 12 | 10.5 | 114.8 | (59.3-200.6) |  | Female | 17 | 12.1 | 140.1 | (81.6-224.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 39 | 39.3 | 99.1 | (70.5-135.5) |
| Female | 288 | 265.3 | 108.6 | (96.4-121.8) |  | Female | 63 | 36.7 | 171.8 | (132.0-219.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 33 | 30.3 | 108.8 | (74.9-152.8) |
| Female | 12 | 8.2 | 146.3 | (75.5-255.7) |  | Female | 14 | 15.0 | 93.2 | (50.9-156.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 62 | 75.6 | 82.1 | (62.9-105.2) |  |  |  |  |  |  |
| Female | 85 | 80.6 | 105.5 | (84.3-130.5) |  | Female | 19 | 23.4 | 81.3 | (48.9-126.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 16 | 17.8 | 90.0 | (51.4-146.1) |  | Male | 23 | 25.3 | 91.0 | (57.7-136.6) |
| Female | 3 | 5.3 | nc | (nc-nc) |  | Female | 23 | 28.6 | 80.3 | (50.9-120.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 4.3 | nc | (nc-nc) |  | Male | 215 | 204.5 | 105.1 | (91.5-120.1) |
| Female | 7 | 3.7 | 191.6 | (76.7-394.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 36.2 | 80.0 | (53.6-114.9) |  | Male | 14 | 17.2 | 81.4 | (44.4-136.5) |
| Female | 12 | 21.8 | 55.0 | (28.4-96.0) |  | Female | 6 | 11.1 | 54.1 | (19.7-117.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 10.1 | 168.6 | (98.1-269.9) |  | Male | 9 | 7.1 | 125.9 | (57.5-239.1) |
| Female | 2 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 27 | 28.2 | 95.8 | (63.1-139.3) |  | Male | 16 | 15.1 | 106.1 | (60.6-172.2) |
| Female | 27 | 21.2 | 127.5 | (84.0-185.5) |  | Female | 44 | 43.6 | 100.9 | (73.3-135.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 22.9 | 78.4 | (46.5-124.0) |  |  |  |  |  |  |
| Female | 13 | 8.5 | 152.9 | (81.3-261.5) |  | Female | 53 | 58.1 | 91.2 | (68.3-119.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 128 | 127.8 | 100.2 | (83.6-119.1) |  | Male | 908 | 884.8 | 102.6 | (96.1-109.5) |
| Female | 159 | 137.8 | 115.4 | (98.1-134.8) |  | Female | 1032 | 938.5 | 110.0 | (103.3-116.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

238

# Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 6 | 7.7 | 78.3 | (28.6-170.4) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 6.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 17 | 25.4 | 67.0 | (39.0-107.3) |
| Female | 1 | 3.7 | nc | (nc-nc) |  | Female | 15 | 25.6 | 58.7 | (32.8-96.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

239

# Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 16.3 | 116.6 | (70.1-182.0) |  | Male | 7 | 11.1 | 63.2 | (25.3-130.2) |
| Female | 7 | 5.8 | 121.3 | (48.6-250.0) |  | Female | 15 | 9.1 | 164.5 | (92.0-271.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 13 | 9.9 | 131.2 | (69.8-224.4) |
| Female | 78 | 75.7 | 103.0 | (81.4-128.6) |  | Female | 8 | 8.8 | 91.4 | (39.4-180.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 8.8 | 135.8 | (70.1-237.3) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 18.6 | 150.2 | (99.8-217.1) |  |  |  |  |  |  |
| Female | 19 | 17.6 | 107.9 | (64.9-168.5) |  | Female | 6 | 6.4 | 94.3 | (34.4-205.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.5 | 110.0 | (35.5-256.8) |  | Male | 7 | 6.1 | 115.6 | (46.3-238.1) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 5 | 5.9 | 85.4 | (27.5-199.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 69 | 58.1 | 118.8 | (92.4-150.4) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 10.2 | 107.8 | (53.8-192.9) |  | Male | 6 | 4.1 | 146.8 | (53.6-319.6) |
| Female | 7 | 5.7 | 122.8 | (49.2-253.1) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 7.0 | 143.2 | (68.6-263.4) |  | Male | 7 | 4.8 | 144.4 | (57.9-297.6) |
| Female | 5 | 5.0 | 99.8 | (32.1-232.8) |  | Female | 24 | 14.8 | 161.7 | (103.6-240.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.1 | nc | (nc-nc) |  | Female | 17 | 17.1 | 99.4 | (57.9-159.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 29.9 | 113.6 | (78.6-158.7) |  | Male | 262 | 227.5 | 115.2 | (101.7-130.0) |
| Female | 46 | 31.3 | 146.8 | (107.5-195.9) |  | Female | 269 | 241.0 | 111.6 | (98.7-125.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

240

# Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 11.0 | 45.4 | (14.6-106.0) |  | Male | 6 | 7.6 | 79.3 | (29.0-172.6) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 2 | 5.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 4 | 1.8 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 6.8 | 73.7 | (23.7-172.0) |
| Female | 52 | 47.2 | 110.1 | (82.2-144.4) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 6.3 | 95.9 | (35.0-208.8) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 13.0 | 107.6 | (58.8-180.6) |  |  |  |  |  |  |
| Female | 15 | 10.5 | 142.8 | (79.9-235.5) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 6 | 4.2 | 144.3 | (52.7-314.0) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 30 | 39.7 | 75.6 | (51.0-107.9) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.0 | 85.1 | (31.1-185.3) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 5 | 3.5 | 141.3 | (45.6-329.9) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.7 | 105.3 | (33.9-245.7) |  | Male | 5 | 3.3 | 150.6 | (48.5-351.5) |
| Female | 4 | 3.0 | nc | (nc-nc) |  | Female | 8 | 9.4 | 85.3 | (36.7-168.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 18 | 10.6 | 169.9 | (100.6-268.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 20.2 | 128.7 | (84.1-188.6) |  | Male | 143 | 155.7 | 91.8 | (77.4-108.2) |
| Female | 17 | 19.2 | 88.6 | (51.6-141.8) |  | Female | 154 | 147.7 | 104.3 | (88.4-122.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

241

# Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 10 | 13.1 | 76.2 | (36.5-140.1) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 4 | 11.6 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

242

# Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 4 | 6.8 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 5.3 | 112.3 | (41.0-244.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 21 | 22.5 | 93.5 | (57.9-142.9) |
| Female | 0 | 3.2 | nc | (nc-nc) |  | Female | 11 | 22.4 | 49.0 | (24.4-87.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

243

# Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 6 | 6.8 | 88.1 | (32.2-191.8) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 9 | 5.7 | 158.5 | (72.3-300.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 2.6 | nc | (nc-nc) |  | Male | 23 | 21.3 | 107.7 | (68.3-161.7) |
| Female | 5 | 2.5 | 197.6 | (63.7-461.2) |  | Female | 21 | 20.7 | 101.5 | (62.8-155.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

244

# Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 70 | 52.9 | 132.4 | (103.2-167.3) |  | Male | 29 | 32.7 | 88.6 | (59.3-127.2) |
| Female | 21 | 20.8 | 100.9 | (62.5-154.3) |  | Female | 22 | 27.0 | 81.6 | (51.1-123.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 9.7 | 144.7 | (79.0-242.8) |  | Male | 10 | 10.6 | 93.9 | (45.0-172.8) |
| Female | 5 | 8.5 | 59.0 | (19.0-137.6) |  | Female | 3 | 9.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 29 | 29.4 | 98.5 | (66.0-141.5) |
| Female | 189 | 215.3 | 87.8 | (75.7-101.2) |  | Female | 26 | 28.4 | 91.6 | (59.8-134.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 31 | 24.2 | 128.0 | (86.9-181.7) |
| Female | 4 | 6.9 | nc | (nc-nc) |  | Female | 10 | 11.8 | 84.7 | (40.5-155.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 62 | 56.1 | 110.6 | (84.8-141.7) |  |  |  |  |  |  |
| Female | 79 | 60.3 | 131.0 | (103.7-163.3) |  | Female | 13 | 18.8 | 69.2 | (36.8-118.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 27 | 13.5 | 200.7 | (132.2-292.0) |  | Male | 18 | 18.6 | 96.5 | (57.2-152.6) |
| Female | 5 | 4.0 | 123.9 | (39.9-289.2) |  | Female | 19 | 21.3 | 89.1 | (53.6-139.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 155 | 164.7 | 94.1 | (79.9-110.2) |
| Female | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 30 | 28.4 | 105.5 | (71.1-150.6) |  | Male | 11 | 12.6 | 87.3 | (43.5-156.3) |
| Female | 21 | 17.4 | 120.6 | (74.6-184.3) |  | Female | 8 | 8.2 | 97.2 | (41.9-191.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 11 | 7.8 | 141.3 | (70.4-252.9) |  | Male | 10 | 6.4 | 156.6 | (75.0-288.0) |
| Female | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 22 | 20.9 | 105.4 | (66.0-159.5) |  | Male | 14 | 12.4 | 112.8 | (61.6-189.3) |
| Female | 9 | 16.4 | 55.0 | (25.1-104.3) |  | Female | 33 | 37.4 | 88.1 | (60.6-123.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 18.0 | 94.4 | (54.9-151.1) |  |  |  |  |  |  |
| Female | 6 | 6.6 | 90.4 | (33.0-196.7) |  | Female | 52 | 48.2 | 107.8 | (80.5-141.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 102 | 93.2 | 109.5 | (89.3-132.9) |  | Male | 726 | 671.7 | 108.1 | (100.4-116.2) |
| Female | 149 | 106.8 | 139.5 | (118.0-163.8) |  | Female | 737 | 741.4 | 99.4 | (92.4-106.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

245

# Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 4 | 3.5 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 9 | 13.3 | 67.9 | (31.0-128.9) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 9 | 11.6 | 77.7 | (35.5-147.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

246

# Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 6.9 | 158.7 | (79.1-283.9) |  | Male | 6 | 5.0 | 120.5 | (44.0-262.3) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 3 | 4.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 4 | 1.6 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 10 | 4.5 | 221.3 | (106.0-407.1) |
| Female | 40 | 36.5 | 109.7 | (78.4-149.4) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 8.5 | 94.0 | (40.5-185.2) |  |  |  |  |  |  |
| Female | 9 | 8.9 | 100.8 | (46.0-191.3) |  | Female | 6 | 3.1 | 194.1 | (70.9-422.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 7 | 2.7 | 256.3 | (102.7-528.1) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 32 | 26.7 | 119.8 | (81.9-169.1) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 4.7 | 212.1 | (101.5-390.0) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 7 | 2.5 | 282.1 | (113.0-581.2) |  | Female | 6 | 7.4 | 80.8 | (29.5-175.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 7 | 8.0 | 87.4 | (35.0-180.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 12.9 | 139.8 | (82.8-221.0) |  | Male | 136 | 102.5 | 132.7 | (111.3-156.9) |
| Female | 20 | 15.4 | 129.7 | (79.2-200.3) |  | Female | 128 | 117.8 | 108.6 | (90.6-129.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

247

# Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 71 | 64.4 | 110.3 | (86.2-139.2) |  | Male | 64 | 41.9 | 152.7 | (117.6-195.0) |
| Female | 22 | 23.7 | 92.8 | (58.1-140.4) |  | Female | 53 | 32.7 | 162.0 | (121.3-211.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 12.7 | 110.5 | (60.3-185.4) |  | Male | 11 | 13.6 | 81.0 | (40.4-144.9) |
| Female | 11 | 10.5 | 104.3 | (52.0-186.7) |  | Female | 10 | 11.0 | 90.8 | (43.5-167.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 48 | 37.5 | 127.9 | (94.3-169.5) |
| Female | 303 | 274.6 | 110.3 | (98.3-123.5) |  | Female | 28 | 33.5 | 83.5 | (55.5-120.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 37 | 32.5 | 113.9 | (80.2-156.9) |
| Female | 6 | 8.8 | 68.2 | (24.9-148.4) |  | Female | 15 | 14.3 | 104.6 | (58.5-172.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 72 | 70.3 | 102.5 | (80.2-129.1) |  |  |  |  |  |  |
| Female | 62 | 69.1 | 89.7 | (68.8-115.0) |  | Female | 34 | 23.3 | 145.7 | (100.9-203.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 20 | 17.4 | 114.7 | (70.0-177.1) |  | Male | 27 | 23.5 | 114.8 | (75.7-167.1) |
| Female | 1 | 4.7 | nc | (nc-nc) |  | Female | 23 | 24.2 | 94.9 | (60.2-142.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 4.9 | nc | (nc-nc) |  | Male | 237 | 222.6 | 106.5 | (93.3-120.9) |
| Female | 1 | 3.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 37 | 38.0 | 97.5 | (68.6-134.3) |  | Male | 12 | 15.7 | 76.3 | (39.4-133.2) |
| Female | 21 | 21.5 | 97.6 | (60.4-149.1) |  | Female | 10 | 9.3 | 107.8 | (51.6-198.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 12 | 10.2 | 117.4 | (60.6-205.1) |  | Male | 6 | 8.7 | 69.3 | (25.3-151.0) |
| Female | 1 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 28 | 26.2 | 107.0 | (71.1-154.7) |  | Male | 23 | 17.1 | 134.5 | (85.2-201.8) |
| Female | 15 | 19.0 | 78.8 | (44.1-130.0) |  | Female | 72 | 48.0 | 149.9 | (117.3-188.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 30 | 23.6 | 127.3 | (85.9-181.8) |  |  |  |  |  |  |
| Female | 6 | 7.9 | 76.0 | (27.8-165.5) |  | Female | 70 | 62.5 | 112.0 | (87.3-141.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 144 | 117.9 | 122.1 | (103.0-143.8) |  | Male | 987 | 866.8 | 113.9 | (106.9-121.2) |
| Female | 144 | 127.3 | 113.1 | (95.4-133.1) |  | Female | 987 | 904.0 | 109.2 | (102.5-116.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

248

# Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 3.5 | 172.5 | (63.0-375.4) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 15 | 12.5 | 119.8 | (67.0-197.7) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 13 | 12.8 | 101.6 | (54.1-173.8) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 6.5 | nc | (nc-nc) |  | Male | 40 | 48.0 | 83.3 | (59.5-113.4) |
| Female | 7 | 5.5 | 128.3 | (51.4-264.5) |  | Female | 50 | 39.8 | 125.7 | (93.3-165.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

249

# Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.2 | 154.1 | (49.6-359.5) |  | Male | 6 | 2.3 | 260.2 | (95.0-566.3) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 4 | 1.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 16 | 16.3 | 98.2 | (56.1-159.5) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 2.0 | 501.4 | (240.1-922.2) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 3.9 | 127.8 | (41.2-298.3) |  |  |  |  |  |  |
| Female | 1 | 3.6 | nc | (nc-nc) |  | Female | 5 | 1.4 | 361.3 | (116.4-843.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 16 | 13.0 | 122.9 | (70.2-199.6) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 2.2 | 227.1 | (73.2-530.0) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 4 | 1.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 6.1 | nc | (nc-nc) |  | Male | 70 | 48.3 | 145.0 | (113.0-183.2) |
| Female | 3 | 6.8 | nc | (nc-nc) |  | Female | 49 | 51.3 | 95.5 | (70.7-126.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

250

# Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 5.6 | nc | (nc-nc) |  | Male | 6 | 3.6 | 167.6 | (61.2-364.9) |
| Female | 5 | 1.7 | 297.5 | (95.9-694.2) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 15 | 17.4 | 86.0 | (48.1-141.9) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 3.0 | 168.8 | (54.4-393.9) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 6.4 | 109.7 | (44.0-226.1) |  |  |  |  |  |  |
| Female | 9 | 4.6 | 195.2 | (89.1-370.6) |  | Female | 4 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 12 | 20.3 | 59.2 | (30.5-103.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 3 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 10 | 10.1 | 98.8 | (47.3-181.8) |  | Male | 74 | 75.8 | 97.6 | (76.6-122.5) |
| Female | 10 | 9.1 | 109.8 | (52.5-201.9) |  | Female | 71 | 59.0 | 120.4 | (94.0-151.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

251

# Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 103 | 94.8 | 108.7 | (88.7-131.8) |  | Male | 53 | 61.4 | 86.3 | (64.7-112.9) |
| Female | 32 | 35.0 | 91.4 | (62.5-129.0) |  | Female | 61 | 50.2 | 121.4 | (92.9-156.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 20 | 19.1 | 104.9 | (64.0-161.9) |  | Male | 14 | 19.4 | 72.1 | (39.4-121.0) |
| Female | 16 | 15.6 | 102.9 | (58.8-167.0) |  | Female | 14 | 16.0 | 87.5 | (47.8-146.8) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 5 | 3.3 | 152.0 | (49.0-354.6) |  | Male | 46 | 55.2 | 83.4 | (61.0-111.2) |
| Female | 382 | 389.5 | 98.1 | (88.5-108.4) |  | Female | 63 | 49.5 | 127.4 | (97.9-163.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 64 | 44.7 | 143.1 | (110.2-182.7) |
| Female | 22 | 13.7 | 160.3 | (100.4-242.7) |  | Female | 25 | 20.8 | 120.3 | (77.8-177.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 133 | 103.1 | 129.0 | (108.0-152.9) |  |  |  |  |  |  |
| Female | 96 | 103.5 | 92.8 | (75.1-113.3) |  | Female | 31 | 33.9 | 91.5 | (62.1-129.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 28 | 24.1 | 116.2 | (77.2-168.0) |  | Male | 27 | 33.9 | 79.6 | (52.5-115.9) |
| Female | 11 | 6.8 | 161.0 | (80.3-288.1) |  | Female | 36 | 35.7 | 100.9 | (70.7-139.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 9 | 8.3 | 107.8 | (49.2-204.7) |  | Male | 254 | 288.8 | 87.9 | (77.5-99.5) |
| Female | 8 | 6.7 | 119.6 | (51.5-235.7) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 48 | 52.9 | 90.8 | (66.9-120.4) |  | Male | 30 | 23.1 | 130.2 | (87.8-185.8) |
| Female | 29 | 31.0 | 93.5 | (62.6-134.3) |  | Female | 15 | 14.0 | 107.3 | (60.0-177.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 14.1 | 120.6 | (70.2-193.1) |  | Male | 18 | 16.5 | 109.1 | (64.6-172.4) |
| Female | 5 | 4.4 | 114.4 | (36.9-266.9) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 26 | 39.1 | 66.4 | (43.4-97.4) |  | Male | 26 | 25.3 | 102.6 | (67.0-150.3) |
| Female | 25 | 28.8 | 86.9 | (56.2-128.3) |  | Female | 59 | 77.0 | 76.6 | (58.3-98.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 62 | 32.6 | 190.0 | (145.7-243.6) |  |  |  |  |  |  |
| Female | 16 | 11.4 | 140.0 | (80.0-227.4) |  | Female | 81 | 86.4 | 93.8 | (74.5-116.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 242 | 167.3 | 144.7 | (127.0-164.1) |  | Male | 1323 | 1227.5 | 107.8 | (102.0-113.7) |
| Female | 237 | 183.5 | 129.2 | (113.3-146.7) |  | Female | 1362 | 1319.7 | 103.2 | (97.8-108.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

252

# Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 34 | 35.8 | 95.0 | (65.8-132.7) |  | Male | 12 | 22.6 | 53.2 | (27.4-92.9) |
| Female | 7 | 13.2 | 52.9 | (21.2-108.9) |  | Female | 15 | 18.6 | 80.5 | (45.0-132.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 6.8 | 88.1 | (32.2-191.8) |  | Male | 7 | 7.3 | 95.9 | (38.4-197.6) |
| Female | 5 | 5.9 | 84.0 | (27.1-196.1) |  | Female | 10 | 6.1 | 164.4 | (78.7-302.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 13 | 20.3 | 63.9 | (34.0-109.3) |
| Female | 127 | 149.9 | 84.7 | (70.6-100.8) |  | Female | 18 | 18.8 | 95.6 | (56.6-151.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 16.6 | 42.3 | (16.9-87.1) |
| Female | 5 | 5.1 | 97.5 | (31.4-227.5) |  | Female | 9 | 7.9 | 113.3 | (51.7-215.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 38 | 38.4 | 99.0 | (70.0-135.8) |  |  |  |  |  |  |
| Female | 44 | 39.0 | 112.7 | (81.9-151.3) |  | Female | 10 | 12.9 | 77.8 | (37.2-143.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 9.1 | 66.0 | (24.1-143.7) |  | Male | 10 | 12.7 | 78.9 | (37.8-145.2) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 7 | 13.5 | 52.0 | (20.8-107.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 2.7 | nc | (nc-nc) |  | Male | 114 | 108.8 | 104.8 | (86.4-125.9) |
| Female | 0 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 22 | 19.5 | 112.8 | (70.7-170.8) |  | Male | 8 | 8.6 | 93.0 | (40.1-183.3) |
| Female | 10 | 11.8 | 84.9 | (40.7-156.2) |  | Female | 6 | 5.3 | 112.3 | (41.0-244.4) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.3 | 113.3 | (41.4-246.5) |  | Male | 0 | 4.9 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 14.4 | 62.4 | (28.5-118.5) |  | Male | 13 | 8.8 | 147.9 | (78.7-252.9) |
| Female | 2 | 10.8 | nc | (nc-nc) |  | Female | 33 | 28.1 | 117.6 | (81.0-165.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 12.3 | 97.9 | (50.5-171.0) |  |  |  |  |  |  |
| Female | 2 | 4.4 | nc | (nc-nc) |  | Female | 35 | 33.6 | 104.2 | (72.6-145.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 38 | 63.2 | 60.1 | (42.6-82.6) |  | Male | 384 | 456.6 | 84.1 | (75.9-93.0) |
| Female | 56 | 69.2 | 80.9 | (61.1-105.1) |  | Female | 434 | 501.1 | 86.6 | (78.7-95.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

253

# Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 13.8 | 122.8 | (71.5-196.5) |  | Male | 8 | 9.2 | 87.2 | (37.6-171.9) |
| Female | 7 | 5.4 | 129.8 | (52.0-267.4) |  | Female | 10 | 7.3 | 136.6 | (65.4-251.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 5 | 2.9 | 173.0 | (55.8-403.8) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 12 | 8.2 | 147.0 | (75.9-256.8) |
| Female | 64 | 59.1 | 108.3 | (83.4-138.2) |  | Female | 6 | 7.5 | 79.9 | (29.2-173.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.2 | 69.6 | (22.4-162.4) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 15.6 | 179.6 | (119.3-259.6) |  |  |  |  |  |  |
| Female | 18 | 15.5 | 116.1 | (68.7-183.4) |  | Female | 5 | 5.1 | 98.0 | (31.6-228.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.7 | 134.7 | (43.4-314.2) |  | Male | 7 | 5.1 | 137.1 | (54.9-282.5) |
| Female | 3 | 1.1 | nc | (nc-nc) |  | Female | 5 | 5.4 | 92.0 | (29.6-214.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 47 | 46.7 | 100.7 | (73.9-133.8) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 8.3 | 157.3 | (83.7-269.1) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 10 | 4.7 | 211.3 | (101.2-388.7) |  | Female | 4 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 4 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 5.8 | nc | (nc-nc) |  | Male | 6 | 3.8 | 159.1 | (58.1-346.3) |
| Female | 4 | 4.3 | nc | (nc-nc) |  | Female | 27 | 10.8 | 249.2 | (164.2-362.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 16 | 13.2 | 120.9 | (69.1-196.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 29 | 25.2 | 115.2 | (77.1-165.5) |  | Male | 219 | 187.3 | 117.0 | (102.0-133.5) |
| Female | 32 | 28.6 | 111.7 | (76.4-157.7) |  | Female | 245 | 199.7 | 122.7 | (107.8-139.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

254

# Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 24.7 | 117.3 | (78.6-168.5) |  | Male | 12 | 16.3 | 73.6 | (38.0-128.5) |
| Female | 11 | 10.2 | 108.2 | (53.9-193.6) |  | Female | 16 | 13.8 | 115.9 | (66.2-188.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.1 | 116.7 | (42.6-254.0) |  | Male | 5 | 5.2 | 95.6 | (30.8-223.2) |
| Female | 7 | 4.5 | 156.3 | (62.6-322.0) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 16 | 14.6 | 109.2 | (62.4-177.4) |
| Female | 131 | 111.9 | 117.1 | (97.9-138.9) |  | Female | 6 | 14.2 | 42.2 | (15.4-92.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 12.7 | 86.4 | (43.1-154.6) |
| Female | 1 | 3.7 | nc | (nc-nc) |  | Female | 7 | 6.0 | 117.2 | (46.9-241.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 27.6 | 119.8 | (82.4-168.2) |  |  |  |  |  |  |
| Female | 23 | 29.8 | 77.1 | (48.9-115.7) |  | Female | 13 | 9.6 | 135.0 | (71.8-230.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 6.7 | 104.8 | (42.0-215.9) |  | Male | 7 | 9.1 | 77.2 | (30.9-159.1) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 9 | 10.4 | 86.6 | (39.5-164.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 62 | 83.9 | 73.9 | (56.7-94.8) |
| Female | 4 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 14.8 | 94.6 | (51.7-158.7) |  | Male | 4 | 6.1 | nc | (nc-nc) |
| Female | 9 | 8.9 | 101.7 | (46.4-193.0) |  | Female | 1 | 4.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 5 | 3.5 | 141.4 | (45.6-330.1) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 10.4 | 125.0 | (66.5-213.8) |  | Male | 7 | 6.9 | 102.0 | (40.9-210.2) |
| Female | 10 | 8.2 | 121.3 | (58.1-223.1) |  | Female | 25 | 20.3 | 122.9 | (79.5-181.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 9.1 | 120.5 | (60.1-215.7) |  |  |  |  |  |  |
| Female | 5 | 3.3 | 150.1 | (48.4-350.4) |  | Female | 27 | 24.9 | 108.6 | (71.6-158.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 36 | 44.7 | 80.5 | (56.3-111.4) |  | Male | 305 | 334.2 | 91.3 | (81.3-102.1) |
| Female | 43 | 52.5 | 81.9 | (59.2-110.3) |  | Female | 391 | 376.8 | 103.8 | (93.7-114.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

255

# Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 13.8 | 58.1 | (25.0-114.6) |  | Male | 8 | 8.9 | 89.9 | (38.7-177.1) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 4 | 5.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.7 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 6 | 8.0 | 74.7 | (27.3-162.6) |
| Female | 44 | 47.5 | 92.6 | (67.3-124.3) |  | Female | 7 | 5.3 | 131.5 | (52.7-270.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 7.1 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 15.3 | 71.9 | (35.9-128.7) |  |  |  |  |  |  |
| Female | 11 | 10.5 | 105.2 | (52.4-188.2) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 1 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 38 | 46.7 | 81.4 | (57.6-111.7) |
| Female | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 8.1 | 74.2 | (27.1-161.5) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 6 | 3.5 | 170.3 | (62.2-370.7) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.6 | 88.6 | (28.5-206.7) |  | Male | 0 | 3.7 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 7 | 9.3 | 75.5 | (30.2-155.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 14 | 11.0 | 127.5 | (69.7-214.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 24.4 | 94.3 | (59.7-141.5) |  | Male | 126 | 184.2 | 68.4 | (57.0-81.4) |
| Female | 17 | 19.1 | 89.1 | (51.9-142.7) |  | Female | 139 | 148.8 | 93.4 | (78.6-110.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

256

# Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 49 | 49.7 | 98.6 | (73.0-130.4) |  | Male | 23 | 33.5 | 68.6 | (43.5-102.9) |
| Female | 15 | 19.6 | 76.4 | (42.7-125.9) |  | Female | 27 | 27.6 | 97.8 | (64.4-142.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 10.8 | 102.0 | (50.8-182.5) |  | Male | 7 | 10.3 | 67.9 | (27.2-139.9) |
| Female | 11 | 8.6 | 127.3 | (63.5-227.8) |  | Female | 9 | 8.9 | 100.8 | (46.0-191.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 30 | 30.0 | 99.9 | (67.4-142.6) |
| Female | 195 | 217.3 | 89.7 | (77.6-103.2) |  | Female | 25 | 27.7 | 90.4 | (58.5-133.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 20 | 24.8 | 80.8 | (49.3-124.8) |
| Female | 5 | 7.5 | 66.8 | (21.5-155.9) |  | Female | 16 | 11.5 | 138.7 | (79.2-225.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 60 | 55.9 | 107.3 | (81.9-138.1) |  |  |  |  |  |  |
| Female | 42 | 57.2 | 73.4 | (52.9-99.2) |  | Female | 14 | 18.8 | 74.5 | (40.7-125.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 12.9 | 62.1 | (26.7-122.4) |  | Male | 24 | 18.0 | 133.5 | (85.5-198.6) |
| Female | 3 | 3.9 | nc | (nc-nc) |  | Female | 14 | 19.9 | 70.3 | (38.4-117.9) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 4.9 | 161.7 | (69.6-318.5) |  | Male | 123 | 155.9 | 78.9 | (65.6-94.1) |
| Female | 8 | 3.5 | 231.5 | (99.7-456.2) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 29.3 | 112.6 | (77.5-158.2) |  | Male | 21 | 12.3 | 170.9 | (105.8-261.3) |
| Female | 27 | 17.3 | 156.0 | (102.8-227.0) |  | Female | 12 | 7.8 | 153.2 | (79.1-267.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 9 | 7.5 | 119.9 | (54.7-227.6) |  | Male | 8 | 10.1 | 79.5 | (34.2-156.6) |
| Female | 7 | 2.4 | 287.9 | (115.4-593.3) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 27 | 21.3 | 126.7 | (83.5-184.4) |  | Male | 11 | 14.9 | 73.9 | (36.9-132.3) |
| Female | 15 | 16.1 | 93.5 | (52.3-154.1) |  | Female | 51 | 41.4 | 123.2 | (91.7-162.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 25 | 17.7 | 141.6 | (91.6-209.0) |  |  |  |  |  |  |
| Female | 7 | 6.4 | 108.9 | (43.6-224.4) |  | Female | 36 | 48.3 | 74.5 | (52.2-103.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 117 | 88.3 | 132.5 | (109.6-158.8) |  | Male | 663 | 663.5 | 99.9 | (92.5-107.8) |
| Female | 136 | 103.1 | 131.9 | (110.7-156.0) |  | Female | 729 | 734.4 | 99.3 | (92.2-106.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

257

# Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 3.4 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 6 | 9.7 | 61.8 | (22.6-134.5) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 9 | 10.2 | 87.9 | (40.1-166.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 6.0 | nc | (nc-nc) |  | Male | 20 | 40.5 | 49.4 | (30.2-76.3) |
| Female | 1 | 5.0 | nc | (nc-nc) |  | Female | 19 | 32.9 | 57.8 | (34.8-90.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

258

# Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 5 | 1.9 | 269.8 | (87.0-629.7) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 26 | 22.4 | 116.2 | (75.9-170.3) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 6.0 | 83.2 | (26.8-194.3) |  |  |  |  |  |  |
| Female | 8 | 5.7 | 140.3 | (60.4-276.5) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 25 | 19.6 | 127.6 | (82.6-188.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 10.0 | 110.0 | (54.8-196.8) |  | Male | 74 | 75.3 | 98.3 | (77.2-123.4) |
| Female | 6 | 9.5 | 63.5 | (23.2-138.1) |  | Female | 67 | 73.5 | 91.1 | (70.6-115.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

259

# Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 17.8 | 112.6 | (68.7-173.9) |  | Male | 14 | 11.9 | 117.7 | (64.3-197.5) |
| Female | 10 | 7.2 | 139.4 | (66.8-256.5) |  | Female | 12 | 9.5 | 126.1 | (65.1-220.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.8 | 132.4 | (42.7-309.0) |  | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 11 | 10.7 | 102.8 | (51.2-183.9) |
| Female | 82 | 79.6 | 103.1 | (82.0-127.9) |  | Female | 17 | 10.0 | 170.4 | (99.2-272.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 9.2 | 108.9 | (52.1-200.2) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 22 | 19.9 | 110.8 | (69.4-167.7) |  |  |  |  |  |  |
| Female | 23 | 20.3 | 113.2 | (71.7-169.9) |  | Female | 6 | 6.7 | 88.9 | (32.5-193.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 4.8 | 165.3 | (71.2-325.8) |  | Male | 7 | 6.5 | 107.0 | (42.9-220.4) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 7 | 7.2 | 97.1 | (38.9-200.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 67 | 61.6 | 108.7 | (84.3-138.1) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 10.8 | 129.9 | (71.0-218.0) |  | Male | 5 | 4.4 | 113.2 | (36.5-264.2) |
| Female | 16 | 6.4 | 251.1 | (143.4-407.8) |  | Female | 8 | 2.7 | 291.6 | (125.5-574.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 7.5 | 133.7 | (64.0-246.0) |  | Male | 3 | 5.1 | nc | (nc-nc) |
| Female | 11 | 5.7 | 194.3 | (96.9-347.6) |  | Female | 19 | 13.9 | 136.6 | (82.2-213.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 6.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 22 | 18.0 | 122.1 | (76.5-184.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 32.5 | 104.6 | (72.4-146.1) |  | Male | 267 | 243.7 | 109.6 | (96.8-123.5) |
| Female | 51 | 38.5 | 132.4 | (98.6-174.1) |  | Female | 324 | 265.7 | 121.9 | (109.0-136.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

260

# Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 11.7 | 77.1 | (35.2-146.3) |  | Male | 8 | 6.9 | 116.5 | (50.2-229.5) |
| Female | 2 | 4.7 | nc | (nc-nc) |  | Female | 7 | 5.5 | 126.5 | (50.7-260.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 3 | 6.1 | nc | (nc-nc) |
| Female | 47 | 46.1 | 102.0 | (74.9-135.6) |  | Female | 5 | 6.2 | 80.8 | (26.0-188.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.0 | 99.4 | (32.0-232.0) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 6 | 2.6 | 232.4 | (84.9-505.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 11.6 | 86.1 | (41.2-158.4) |  |  |  |  |  |  |
| Female | 5 | 13.3 | 37.7 | (12.1-87.9) |  | Female | 5 | 4.1 | 123.4 | (39.8-287.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.0 | nc | (nc-nc) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 3 | 4.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 40 | 37.2 | 107.6 | (76.8-146.5) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 5.9 | 135.0 | (58.1-266.1) |  | Male | 0 | 2.7 | nc | (nc-nc) |
| Female | 6 | 3.8 | 158.9 | (58.0-345.9) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 5 | 6.8 | 73.7 | (23.8-172.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 9 | 10.6 | 85.2 | (38.9-161.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 21.0 | 76.2 | (43.5-123.8) |  | Male | 130 | 144.3 | 90.1 | (75.3-107.0) |
| Female | 14 | 24.2 | 57.7 | (31.5-96.9) |  | Female | 141 | 160.0 | 88.1 | (74.2-103.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

261

# Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 4 | 8.6 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 2 | 7.2 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

262

# Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.9 | 102.0 | (37.2-222.0) |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 5 | 3.4 | 147.6 | (47.6-344.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 26 | 27.8 | 93.5 | (61.1-137.0) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 3 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 9 | 6.7 | 133.5 | (60.9-253.5) |  |  |  |  |  |  |
| Female | 7 | 7.0 | 100.2 | (40.1-206.4) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 5 | 2.3 | 216.3 | (69.7-504.8) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 21 | 23.9 | 87.8 | (54.3-134.2) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.9 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.5 | nc | (nc-nc) |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.9 | nc | (nc-nc) |  | Female | 8 | 5.2 | 153.3 | (66.0-302.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 4 | 6.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 11.2 | 98.3 | (49.0-176.0) |  | Male | 78 | 86.4 | 90.3 | (71.4-112.7) |
| Female | 5 | 11.8 | 42.2 | (13.6-98.6) |  | Female | 83 | 90.2 | 92.0 | (73.3-114.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

263

# Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 9 | 5.4 | 165.8 | (75.7-314.8) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 10 | 5.2 | 192.2 | (92.0-353.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 21 | 20.5 | 102.4 | (63.4-156.6) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 19 | 17.1 | 111.1 | (66.9-173.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

264